Toxicokinetics in infants and children in relation to the ADI and TDI

Food Additives and Contaminants

Volumn 15, Issue , 1998, Pages 17-35

  Renwick, A G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

ADI (Acceptable Daily Intake); Children; Developmental changes; Maturation (elimination processes); Neonate; Toxicokinetics

Indexed keywords

FOOD ADDITIVE;

ADULT; CHILD; CHILD DEVELOPMENT; CONFERENCE PAPER; DATA BASE; DRUG ELIMINATION; FOOD INTAKE; HUMAN; INFANT; KIDNEY FUNCTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICOKINETICS; WEANING; XENOBIOTIC METABOLISM;

AGE FACTORS; ANIMALS; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT; INTESTINAL ABSORPTION; MAXIMUM ALLOWABLE CONCENTRATION; RATS; XENOBIOTICS;

EID: 0031934439     PISSN: 0265203X     EISSN: 14645122     Source Type: Journal    
DOI: 10.1080/02652039809374612     Document Type: Article

References (120)

1. Aarons, L., 1996, Population approaches/sparse data analysis for human variability in kinetics and dynamics. Environmental Toxicology and Pharmacology, 2, 197-199.
2. Allen Webb, E. M., Ross, M. P., Pappas, J. B., McGough, E. C., and Banner, W., 1994, Age-related amrinone pharmacokinetics in a pediatric population. Critical Care Medicine, 22, 1016-1024.
3. Autret, E., Dutertre, J. P., Breteau, M., Jonville, A. P., Furet, Y., and Laugier, J., 1993, Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. Developmental Pharmacology and Therapeutics, 20, 129-134.
4. BairdLambert, J., Doyle, P. E., Thomas, D., Cvejic, M., and Buchanan, N., 1984, Pharmacokinetics of cefotaxime in neonates. Journal of Antimicrobial Chemotherapy, 13, 471-477.
5. Barrett, D. A., Simpson, J., Rutter, N., Kurihara-Bergstrom, T., Shaw, P. N., and Davis, S. S., 1993, The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. British Journal of Clinical Pharmacology, 36, 215-219.
6. Barrett, D. A., Barker, D. P., Rutter, N., Pawula, M., and Shaw, P. N., 1996, Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusion. British Journal of Clinical Pharmacology, 41, 531-537.
7. Battino, D., Estienne, M., and Avanzini, G., 1995a, Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: phénobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clinical Pharmacokinetics, 29, 257-286.
8. Battino, D., Estienne, M., and Avanzini, G., 1995b, Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II: phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clinical Pharmacokinetics, 29, 341-369.
9. Besunder, J. B., Reed, M. D., and Blumer, J. L., 1988a, Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clinical Pharmacokinetics, 14, 189-216.
10. Besunder, J. B., Reed, M. D., and Blumer, J. L., 1988b, Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). Clinical Pharmacokinetics, 14, 261-286.
11. Bhargava, V. D., and Garrettsson, L. K., 1988, Development of phénobarbital glucosidation in the human neonate. Developmental Pharmacology and Therapeutics, 11, 8-13.
12. Bhat, R., Chari, G., Gulati, A., Aldana, O., Velamati, R., and Bhargava, H., 1990, Pharmacokinetics of a single dose of morphine in preterm infants durng the first week of life. Journal of Pediatrics, 117, 477-481.
13. Blumer, J. L., Reed, M. D., Kearns, G. L., Jacobs, R. F., Gooch, W. M., Yoger, R., Williams, K., and Ewing, B. J., 1995, Sequential, single-dose pharmacokinetic evaluation of mero-penem in hospitalised infants and children. Antimicrobial Agents and Chemotherapy, 39, 1721-1725.
14. Borlakoglu, J. T., Scott, A., Henderson, C. J., and Wolf, C. R., 1993, Expression of P450 isoenzymes during rat liver organogenesis. International Journal of Biochemistry, 25, 1659-1668.
15. Bortolotti, A., Corada, M., Barzago, M. M., Celardo, A., Guaitani, A., and Bonati, M., 1991, Pharmacokinetics of theophylline in the newborn and adult rabbit: in vivo and isolated perfused liver approaches. Drug Metabolism and Disposition, 19, 430-435.
16. Boucher, F. D., Modlin, J. F., Weller, S., Ruff, A., Mirochnick, M., Pelton, S., Wilfert, C., McKinney, R., Crain, M. J., Elkins, M.M., Blum, R., and Prober, C. G., 1993, Phase I evaluation of zidovidine administered to infants exposed at birth to human immunodeficiency virus. Journal of Pediatrics, 122, 137-144.
17. Boville, J. G., 1991, Pharmacokinetics of opioid agonists and antagonists. Bailliere's Clinical Anaesthesiology, 5, 593-613.
18. Brammer, K. W., and Coates, P. E., 1994, Pharmacokinetics of fluconazole in pediatric patients. European Journal of Clinical Microbiology and Infectious Diseases, 13, 325-329.
19. Brashear, W. T., Kuhnert, B. R., and Wei, R., 1988, Maternal and neonatal urinary excretion of sulfate and glucuronide ritodrine conjugates. Clinical Pharmacology and Therapeutics, 44, 634 - 641.
20. Bueva, A., and Guignard, J. P., 1994, Renal function in preterm infants. Pediatric Research, 36, 572-577.
21. Butler, D. A., Kuhn, R. J., and Chandler, M. H. H., 1994, Pharmacokinetics of anti-infective agents in paediatric patients. Clinical Pharmacokinetics, 26, 374-395.
22. Cazeneuve, C., Pons, G., Rey, E., Treluyer, J.-M., Cresteil, T., Thiroux, G., D’Athis, P., and Olive, G., 1994, Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. British Journal of Clinical Pharmacology, 37, 405-412.
23. Chay, P. C. W., Duffy, B. J., and Walker, J. S., 1992, Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clinical Pharmacology and Therapeutics, 51, 334-342.
24. Choonara, I. A., McKay, P., Hain, R., and Rane, A., 1989, Morphine metabolism in children. British Journal of Clinical Pharmacology, 28, 599-604.
25. Choonara, C., Lawrence, A., Michalkiewicz, A., Bowhay, A., and Ratcliffe, J., 1992, Morphine metabolism in neonates and infants. British Journal of Clinical Pharmacology, 34, 434-437.
26. Cresteil, T., 1998, Onset of xenobiotic metabolism in children: toxicological implications. Food Additives and Contaminants, 15, Supplement, 45-51.
27. Cuzzolin, L., Fanos, V., Zambreri, D., Padovani, E. M., and Be-noni, G., 1991, Pharmacokinetics and renal tolerance of aztreonam in premature infants. Anti-microbial Agents and Chemotherapy, 35, 1726-1728.
28. Donelli, M. G., Zucchetti, M., Robatto, A., Perlangeli, V., D’Incalci, M., Masera, G., and Rossi, M. R., 1995, Pharmacokinetics of HD-MTX in infants, children and adolescents with non-p lymphoblastic leukemia. Medical and Pediatric Oncology, 24, 154-159.
29. Fisher, D. M., Canfell, P. C., Spellman, M. J., and Miller, R. D., 1990, Pharmacokinetics and pharmacodynamics of atracurium in infants and children. Anesthiology, 73, 33-37.
30. Fleck, C., 1992, Renal transport of endogenous amino acids I. Comparison between immature and adult rats. Renal Physiology and Biochemistry, 15, 257-265.
31. Fontana, M., Massironi, E., Vaglia, P., Gancia, G. P., Tagliabue, P., and Principi, N., 1993, Ranitidine pharmacokinetics in newborn infants. Archives of Diseases in Childhood, 68, 602-603.
32. Fujii, R., 1990, Investigation of half-life and clinical effects of ceftizoxine in premature and newborn infants. Drug Investigation, 2, 143-149.
33. Fujii, R., Fujita, K., Murono, K., Saijo, M., Kakuya, F., Yoshioka, H., Maruyama, S., Sakata, H., Hiramoto, A., Inyaku, F., Abe, T., Hashira, S., Meguro, H., Azagami, S., Isohata, E., Takeda, S., Kin, Y., Oikawa, T., and Osani, M., 1993, Pharmacokinetics and clinical studies of flomoxef in neonates and premature infants. A study of flomoxef in the perinatal collaborative research group. Japanese Journal of Antibiotics, 46, 518-538.
34. Furlanut, M., Benetello, P., Baraldo, M., Zara, G., Montanari, G., and Donzelli, F., 1990, Chlopromazine disposition in relation to age in children. Clinical Pharmacokinetics, 18, 329-331.
35. Girgensohn, S. C., Schofer, O., Bockisch, A., Meisinger, C., Beetz, R., and Hahn, K., 1991, Preliminary ‘normal values’ for the 99mTc-mercaptoacetyltriglycine (MAG3) clearance in infants. NUC Compact, 22, 84-87.
36. Green, M. D., and Fischer, L. J., 1984, Hepatotoxicity of acetaminophen in neonatal and young rats. II. Metabolic aspects. Toxicology and Applied Pharmacology, 74, 125-133.
37. Green, M. D., Shires, T. K., and Fischer, L. J., 1984, Hepatotoxicity of acetaminophen in neonatal and young rats. I. Age-related changes in susceptibility. Toxicology and Applied Pharmacology, 74, 116-124.
38. Grunert, D., Schonig, M., and Rosendahl, W., 1990, Renal blood flow and flow velocity in children and adolescents. European Journal of Pediatrics, 149, 287-292.
39. Hartley, R., Green, M., Quinn, M. W., Rushforth, J. A., and Le-vene, M. I., 1994, Development of morphine glucuronidation in premature neonates. Biology of the Neonate, 66, 1-9.
40. Hartvig, P., Larsson, E., and Joachimsson, P. O., 1993, Postoperative analgesia and sedation following pediatric cardiac surgery using constant infusion of ketamine. Journal of Cardiothoracic and Vascular Anesthesia, 7, 148-153.
41. Heaton, G. D., and Renwick, A. G., 1991a, The effects of high dietary concentrations of saccharin on in vitro metabolism of xenobiotics in rats. Food and Chemical Toxicology, 29, 297-303.
42. Heaton, G. D., and Renwick, A. G., 1991b, The effects of high dietary concentrations of saccharin on in vivo metabolism of xenobiotics in rats. Food and Chemical Toxicology, 29, 305-312.
43. Heimann, G., 1980, Enteral absorption and bioavailability in relation to age. European Journal of Clinical Pharmacology, 18, 43-50.
44. Hindmarsh, K. W., Górecki, D. K. J., Sankaran, K., and Mayers, D. J., 1991, Chloral hydrate administration to neonates: potential toxicological implications. Journal of the Canadian Society of Forensic Science, 24, 239-245.
45. Hirate, J., Zhu, C., Horikoshi, I., and Bhargava, V. O., 1991, Age-dependent changes in first pass metabolism of acetaminophen in rats. Biopharmaceutics and Drug Disposition, 12, 119 - 126.
46. Holt, D. E., Hurley, R., and Harvey, D., 1995, The metabolism of chloramphenicol by glutathione-S-transferase in human fetal and neonatal liver. Biology of the Neonate, 67, 230-239.
47. Hoppu, K., 1987, Age differences in trimethoprim pharmacokinetics: need for revised dosing in children. Clinical Pharmacology and Therapeutics, 42, 336-343.
48. Huisemande Boer, J. J., Van den Anker, J. N., Vogel, M., Goes-sens, W. H. F., Schoemaker, R. C., and De Groot, K., 1995, Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrobial Agents and Chemotherapy, 39, 431-434.
49. Iwasaki, K., Shiraga, T., Takeshita, K., Katashima, M., Nagase, K., Tada, K., Noda, K., and Noguchi, H., 1993, Perinatal development of amine, alcohol and phenol sulfoconjugations in the rat. Research Commuications in Chemical Pathology and Pharmacology, 81, 183-190.
50. JacqzAigrain, E., Wood, C., and Robieux, I., 1990, Pharmacokinetics of midazolam in critically ill neonates. European Journal of Clinical Pharmacology, 39, 191-192.
51. Kacet, N., Rousell Delvallez, M., Gremillet, C., Dubos, J. P., Storme, L., and Lequien, P., 1992, Pharmacokinetic study of piperacillin in newborns relating to gestational age and postnatal development. Pediatric Infectious Disease Journal, 11, 365-369.
52. Kauffman, R. E., and Kearns, G. L., 1992, Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clinical Pharmacokinetics, 23, 10-29.
53. Kearns, G. L., 1992, Desacetylcefotaxime. Clinical implications of an active metabolite in infants and children. Drug Investigation, 4, 9-17.
54. Kearns, G. L., and Reed, M. D., 1989, Clinical pharmacokinetics in infants and children: a reappraisal. Clinical Pharmacokinetics, 17, SI, 29-67.
55. Kearns, G. L., and Young, R. A., 1994, Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use. Clinical Pharmacokinetics, 26, 169-189.
56. Kearns, G. L., Darville, T., Wells, T. G., Jacobs, R. F., Hughes, G. S., and Borins, M. T., 1994, Single dose pharmacokinetics of cefpodoxime proxetil in infants and children. Drug Investigation, 7, 221-233.
57. Kershaw, W. C., Lehman-McKeeman, L. D., and Klaassen, C. D., 1990, Hepatic isometallothioneins in mice: induction in adults and postnatal ontogeny. Toxicology and Applied Pharmacology, 104, 267-275.
58. Killian, A., Davis, P. J., Stiller, R. L., Cicco, R., Cook, D. R., and Guthrie, R. D., 1990, Influence of gestational age on pharmacokinetics of alfentanil in neonates. Developmental Pharmacology and Therapeutics, 15, 82-85.
59. Klein, D., Scholz, P., Drasch, C. A., MullerHocker, J., and Summer, K. H., 1991, Metallothionein, copper and zinc in fetal and neonatal human liver: changes during development. Toxicology Letters, 56, 61-67.
60. Koren, G., Butt, W., Chinyanga, H., Soldin, S., Tan Y. K., and Pape, K., 1985, Post-operative morphine infusion in newborn infants: assessment of disposition characteristics and safety. Journal of Pediatrics, 107, 963-967.
61. Krzeska, L., Yeates, R. A., and Pfaff, G., 1993, Single dose intravenous pharmacokinetics of fluconazole in infants. Drugs under Experimental and Clinical Research, 19, 267-271.
62. Le Bel, M., Ferron, L., Masson, M., Pichette, J., and Carrier, C., 1988, Benzyl alcohol metabolism and elimination in neonates. Developmental Pharmacology and Therapeutics, 11, 347-356.
63. Lee, T. C., Charles, B. G., Steer, P. A., Flenady, V. J., and Grant, T. C., 1996, Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. British Journal of Clinical Pharmacology, 41, 191 - 200.
64. Lehman-McKeeman, L. D., Andrews, G. K., and Klaassen, C. D., 1988, Ontogeny and induction of hepatic isometallothioneins in immature rats. Toxicology and Applied Pharmacology, 92, 1017.
65. Long, D., Koren, G., and James, A., 1987, Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates. Journal of Pediatrics, 111, 918-921.
66. Lugo, R. A., Nahata, M. C., Menke, J. A., and McCleod, R. E., 1996, Pharmacokinetics of dexamethasone in premature neonates. European Journal of Clinical Pharmacology, 49, 477-483.
67. Lum, P. Y., Walker, S., and Ioannides, C., 1985, Foetal and neonatal development of cytochrome P-450 and cytochrome P448 catalysed mixed fuction oxidase in the rat: induction by 3-methylcholanthrene. Toxicology, 35, 307-317.
68. Lynn, A. M., and Slattery, J. T., 1987, Morphine pharmacokinetics in early infancy. Anesthesiology, 66, 136-139.
69. Manering, G. J., 1985, Drug metabolism in the newborn. Federation Proceedings, 44, 2302-2308.
70. Marik, P. E., Havlik, I., Monteagudo, F. S. E., and Lipman, J., 1991, The pharmacokinetics of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. Journal of Antimicrobial Chemotherapy, 27, 81-89.
71. Mayers, D. J., Hindmarsh, K. W., Sankaran, K., Górecki, D. K. J., and Kasian G. F., 1991, Chloral hydrate disposition following single-dose administration to critically ill neonates and children. Developmental Pharmacology and Therapeutics, 16, 71-77.
72. McLeod, H. L., Krynetski, E. Y., Wilimas, J. A., and Evans, W. E., 1995, Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics, 5, 281-286.
73. McNamara, P. J., Burgio, P., and Yoo, S. D., 1992, Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring: predictions of breast milk to serum concentration ratios. Drug Metabolism and Disposition, 20, 302-308.
74. McRorie, T. I., Lynn, A. M., Nespeca, M. K., Opheim, K. E., and Slattery, J. T., 1992, The maturation of morphine clearance and metabolism. American Journal of Diseases of Children, 146, 972-976.
75. Meek, B., 1996, Assessment of priority substrates under the Canadian Environmental Protection Act. Variations in exposure and response. Environmental Toxicology and Pharmacology, 2, 111-114.
76. Moore, R. A., Baldwin, D., Allen, M. C., Watson, P. J. Q., Bul-lingham, R. E. S., and McQuay, H. J., 1984, Sensitive and specific morphine radioimmunoassay with iodine label: pharmacokinetics of morphine in man after intravenous administration. Annals of Clinical Biochemistry, 21, 318-325.
77. Morselli, P. L., 1989, Clinical pharmacology of the perinatal period in early infancy. Clinical Pharmacokinetics, 17, SI, 13-28.
78. Mukhtar, H., and Bickers, D. R., 1983, Age-related changes in benzo(u)pyrene metabolism and epoxide-metabolising enzyme activities in rat skin. Drug Metabolism and Disposition, 11, 562-567.
79. Nahata, M. C., Miser, A. W., and Reuning, R. H., 1985, Variation in morphine pharmacokinetics in children with cancer. Developmental Pharmacology and Therapeutics, 8, 182-188.
80. Nielsen, P., Friis, C., Gyrdhansen, N., and Kraul, I., 1991, Disposition of parathion in neonatal and young pigs. Pharmacology and Toxicology, 69, 233-237.
81. Notarianni, L. J., Oldham, H. G., and Bennett, P. N., 1987, Passage of paracetamol into breast milk and its subsequent metabolism by the neonate. British Journal of Clinical Pharmacology, 24, 63-67.
82. Odum, J., and Orton, T. C., 1983, Hepatic microsomal glucuronida-tion of clofibric acid in the adult and neonate albino rat. Biochemical Pharmacology, 32, 3565-3569.
83. Olkkola, K. T., Hamunen, K., and Maunuksela, E.-L., 1995, Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clinical Pharmacokinetics, 28, 385 -404.
84. Paap, C. M., and Nahata, +M. C., 1990, Clinical pharmacokinetics of antibacterial drugs in neonates. Clinical Pharmacokinetics, 19, 280-318.
85. Pacifici, G. M., and Rane, A., 1981, Intestinal and hepatic morphine glucuronidation in immature and pregnant rats. Developmental Pharmacology and Therapeutics, 3, 160-167.
86. Pacifici, G. M., Franchi, M., Giuliani, L., and Rane, A., 1990, Development of the glucuronyltransferase and sulfotransferase towards 2-naphthol in human fetus. Developmental Pharmacology and Therapeutics, 14, 108-114.
87. Parker, K. M., and Lera, T. A., 1992, Acute isopropanol ingestion: pharmacokinetic parameters in the infant. American Journal of Emergency Medicine, 10, 542 -544.
88. Paton, D. M., and Webster, D. R., 1985, Clinical pharmacokinetics of Hi-receptor antagonists (the antihistamines). Clinical Pharmacokinetics, 10, 471-497.
89. Peltola, H., Vaarala, M., Renkonen, O. V., and Neuvonen, P. J., 1992, Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrobial Agents and Chemotherapy, 36, 1086-1090.
90. Penna, A., and Buchanan, N., 1991, Paracetamol poisoning in children and hepatotoxicity. British Journal of Clinical Pharmacology, 32, 143-149.
91. Phelps, S. J., Kamper, C. A., Bottorff, M. B., and Alpert, B. S., 1987, Effect of age and serum creatinine on endogenous digoxin-like substances in infants and children. Journal of Pediatrics, 110, 136-139.
92. Pokela, M. L., Olkkola, K. T., Koivisto, M., and Ryhanen, P., 1992, Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. Clinical Pharmacology and Therapeutics, 52, 342-349.
93. Pokela, M. L., Olkkola, K. T., Seppala, T., and Koivisto, M., 1993, Age-related morphine kinetics in infants. Developmental Pharmacology and Therapeutics, 20, 26-34.
94. Provoost, A. P., de Keijzer, M. H., Wolff, E. D., and Molenaar, J. C., 1983, Development of renal function in the rat. The measurement of GFR and EPPF and correlation to body weight and kidney weight. Renal Physiology, 6, 1-9.
95. Regazzi, M. B., Locatelli, F., Buggia, I., Bonetti, F., Zecca, M., Pregnolato, M., and Quaglini, S., 1993, Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation. Clinical Pharmacology and Therapeutics, 54, 45-52.
96. Renwick, A. G., 1991, Safety factors and establishment of acceptable daily intakes. Food Additives and Contaminants, 8, 135-150.
97. Renwick, A. G., 1993, Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Additives and Contaminants, 10, 275-305.
98. Roberts, I., Robinson, M. J., Mughad, M. Z., Ratcliffe, J. G., and Prescott, L. F., 1984, Paracetamol metabolites in the neonate following maternal overdose. British Journal of Clinical Pharmacology, 18, 201-206.
99. Rodman, J. H., 1994, Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. Journal of Adolescent Health, 15, 654-662.
100. Rondanelli, R., Regazzi, M. B., Stronati, M., Cahri, M., Lombardi, G., and Rondini, G., 1992, Ceftriaxone pharmacokinetics in infants younger than three months. Pediatria Medica e Chirurgica, 14, 55-59.
101. Saxen, H., Hoppu, K., and Pohjavuori, M., 1993, Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clinical Pharmacology and Therapeutics, 54, 269-277.
102. Schilter, B., Renwick, A. G., and Huggett, A. C., 1996, Limits for pesticide residues in infant foods: a safety-based proposal. Regulatory Toxicology and Pharmacology, 24, 126-140.
103. Stanski, D. R., Paalzow, L., and Edlund, P. O., 1982, Morphine pharmacokinetics: GLC assay versus radioimmunoassay. Journal of Pharmaceutical Science, 71, 314-317.
104. Steinberg, C., and Notterman, D. A., 1994, Pharmacokinetics of cardiovascular drugs in children. Clinical Pharmacokinetics, 27, 345-367.
105. Sunouchi, M., Takanaka, A., Mizokami, K., Inoue, K., Fujimori, K., Kasuya, Y., and Omon, Y., 1984, Comparison of hepatic drug-metabolising enzymes induced by 3-methylcholanthrene and phénobarbital between pre- and postnatal rats. Toxicology and Applied Pharmacology, 73, 457-463.
106. Tassonyi, E., Pittet, J. F., Schopfer, C. N., Rouge, J. C., Gem-perle, G., Wilder Smith, O. H. G., and Morel, D. R., 1995, Pharmacokinetics of pipecuronium in infants, children and adults. European Journal of Drug Metabolism and Pharmacokinetics, 20, 203-208.
107. Thompson, A. H., and Brodie, M. J., 1992, Pharmacokinetic optimisation of anticonvulsant therapy. Clinical Pharmacokinetics, 23, 216-230.
108. Trang, J. M., Kidd, L., Gruber, W., Storch, G., Demmler, G., Jacobs, R., Dankner, W., Starr, S., Pan, R., Stagno, S., Alford, C., Soong, S. J., Whitley, R. J., and Sommadossi, J. P., 1993, Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalo virus infections. Clinical Pharmacology and Therapeutics, 53, 15-21.
109. Van Den Anker, J. N., Hop, W. C. J., Schoemaker, R. C., Van Der Heijden, B. T., Neijens, H. J., and De Groot, R., 1995, Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. British Journal of Clinical Pharmacology, 40, 439 -443.
110. Vandenberghe, H., MacLeod, S., Chinyanga, H., Endrenyi, L., and Soldrin, S., 1983, Pharmacokinetics of intravenous morphine in balanced anaesthesia: studies in children. Drug Metabolism Reviews, 14, 887-903.
111. Vassal, G., Fischer, A., Challine, D., Boland, I., Ledheist, F., Lemerle, S., Vilmer, E., Rahimy, C., Souillet, G., Gluck-man, E., Michel, G., Deroussent, A., and Goyette, A., 1993, Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood, 82, 1030 - 1034.
112. Vicas, I. M. O., and Beck, R., 1993, Fatal inhalational isopropyl alcohol poisoning in a neonate. Journal of Toxicology -Clinical Toxicology, 31, 473-481.
113. Watkins, J. B., and Klaassen, C. D., 1985, Development of UDP-glucuronosyltransferase activity towards digitoxigenin-monodi-gitoxoside in neonatal rats. Drug Metabolism and Disposition, 13, 186-191.
114. WHO, 1987, Principles for the safety assessment of food additives and contaminants in food. Environmental Health Criteria No. 70 (Geneva: World Health Organization).
115. WHO, 1994, Assessing human health risks of chemicals: derivation of guidance values for health-based exposure limits. Environmental Health Criteria No. 170 (Geneva: World Health Organization).
116. Wiest, D. B., Ohning, B. L., and Garner, S. S., 1991, The disposition of alfentanil in neonates with respiratory distress. Pharmacotherapy, 11, 308-311.
117. WINTERGERST, U., ROLINSKI, B., VOCKS HAUCK, M., WAHN, V., DE-batin, K. M., Notheis, G., Grosch Worner, I., Goebel, F. D., Roscher, A. A., and Belohradsky, B. H., 1995, Pharmacokinetics of orally administered zidovidine in HIV-infected children and adults. Infection, 23, 344-348.
118. Wishart, G. J., 1978, Functional heterogeneity of UDP-glucurono-syltransferase as indicated by its differential development and inducibility by glucocorticoids. Biochemical Journal, 174, 485 - 489.
119. Yamakawa, T., Itoh, S., and Onishi, S., 1984, Developmental changes in hepatic esterase activity towards chloramphenicol succinate and its Michaelis-Menten constant of liver, kidney and lung in humans. Developmental Pharmacology and Therapeutics, 7, 205-212.
120. Yung, B. C. K., and Sostre, S., 1994, Kidney to liver ratio: a simple scintigraphic parameter for routine individual renal function assessment in children. Clinical Nuclear Medicine, 19, 228-232.